SAG is currently inclinical development and has been evaluated in phase II trials in NSCLC [53]; [54] thereforeinvestigations whether mutational status of TP53 could serve as predictive biomarkerin clinical trials warrants further investigation. This evidence concerns the gene SAG and non-small cell lung carcinoma.